Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
March 16, 2023
Ryan Allway March 16th, 2023 Psychedelics, Top News Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel / Vancouver, Canada, March 16, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and... Read more
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
Ryan Allway February 22nd, 2023 Psychedelics, Top News The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc’s PEA Tel Aviv, Israel / Vancouver, Canada, Feb. 22, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:... Read more
REPEAT – Irwin Naturals Closes Acquisition of Leading Kentucky Clinic adding $3 Million in Projected EBITDA, Company delivering on ambitious strategy to build largest global network of mental health clinics
Kentucky February 21, 2023
Ryan Allway February 21st, 2023 Psychedelics, Top News LOS ANGELES, Feb. 21, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) is pleased to announce the Company has successfully completed the acquisition of Serenity Health, LLC, (“Serenity”) one of the leading ketamine clinics in... Read more
Silo Wellness Oregon Psilocybin Update, Jamaica Retreat Article, Director Resignation
Oregon February 17, 2023
Ryan Allway February 17th, 2023 Psychedelics, Top News Springfield, Oregon–(Newsfile Corp. – February 17, 2023) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) announced today that its Oregon attorneys have agreed to handle land use compatibility statements and overnight accommodation approval on a contingent fee agreement (“win fee”)... Read more
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
Ryan Allway February 15th, 2023 Psychedelics, Top News The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),... Read more
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
February 3, 2023
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Ryan Allway February 2nd, 2023 News, Psychedelics, Top News LOS ANGELES, Feb. 02, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today that the Company has secured a credit facility as of February 1, 2023 with its existing commercial lender for up... Read more
Kaya Holdings, Inc. (OTCQB:KAYS) Launches Fifth Dimension Therapeutics(TM) to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and address the Growing Multi-Billion Dollar Global Psychedelics Market
Oregon January 25, 2023
Ryan Allway January 25th, 2023 Psychedelics, Top Story FT. LAUDERDALE, FL / ACCESSWIRE / January 25, 2023 / Kaya Holdings, Inc., (“KAYS” or the “Company”) (OTCQB:KAYS), a pioneer in the U.S. cannabis industry, announced today that it has launched Fifth Dimension Therapeutics™ (“FDT”), which will seek to provide psychedelic “mind... Read more
Ryan Allway January 24th, 2023 Psychedelics, Top News VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) and its manufacturing partners have received an export permit... Read more
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
December 13, 2022
Ryan Allway December 13th, 2022 News, Psychedelics Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) (“Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, today announced it has completed IND-enabling studies on its CMND-100 (MEAI- based)... Read more
